Zymeworks Valuation

Is ZYME undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZYME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ZYME's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZYME's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZYME?

Other financial metrics that can be useful for relative valuation.

ZYME key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9x
Enterprise Value/EBITDA-4.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ZYME's PS Ratio compare to its peers?

The above table shows the PS ratio for ZYME vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average18.2x
AUPH Aurinia Pharmaceuticals
4.9x17.5%US$998.1m
SLN Silence Therapeutics
39.3x28.4%US$898.5m
NRIX Nurix Therapeutics
24.4x26.5%US$1.4b
BCRX BioCryst Pharmaceuticals
4x15.6%US$1.5b
ZYME Zymeworks
15x8.2%US$937.8m

Price-To-Sales vs Peers: ZYME is good value based on its Price-To-Sales Ratio (15x) compared to the peer average (18.2x).


Price to Earnings Ratio vs Industry

How does ZYME's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.4%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.4%
n/an/an/a
No more companies

Price-To-Sales vs Industry: ZYME is expensive based on its Price-To-Sales Ratio (15x) compared to the US Biotechs industry average (11.5x).


Price to Sales Ratio vs Fair Ratio

What is ZYME's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZYME PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: ZYME is expensive based on its Price-To-Sales Ratio (15x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZYME forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$13.20
US$13.90
+5.3%
23.8%US$21.00US$10.00n/a8
Oct ’25US$12.35
US$13.90
+12.6%
23.8%US$21.00US$10.00n/a8
Sep ’25US$11.73
US$14.19
+21.0%
25.7%US$21.00US$10.00n/a9
Aug ’25US$10.11
US$14.08
+39.2%
24.5%US$20.00US$10.00n/a9
Jul ’25US$8.61
US$13.94
+61.9%
26.0%US$20.00US$10.00n/a8
Jun ’25US$8.48
US$13.72
+61.8%
25.3%US$20.00US$10.00n/a9
May ’25US$8.76
US$14.17
+61.7%
26.1%US$21.00US$10.00n/a9
Apr ’25US$9.88
US$14.17
+43.4%
26.1%US$21.00US$10.00n/a9
Mar ’25US$12.51
US$13.28
+6.1%
28.2%US$19.00US$8.00n/a9
Feb ’25US$10.98
US$13.37
+21.8%
27.8%US$19.00US$8.00n/a10
Jan ’25US$10.39
US$13.37
+28.7%
27.8%US$19.00US$8.00n/a10
Dec ’24US$9.15
US$13.52
+47.7%
26.4%US$19.00US$8.00n/a11
Nov ’24US$7.02
US$13.52
+92.6%
27.5%US$19.00US$8.00n/a11
Oct ’24US$6.34
US$13.52
+113.2%
27.5%US$19.00US$8.00US$12.3511
Sep ’24US$7.49
US$13.52
+80.5%
27.5%US$19.00US$8.00US$11.7311
Aug ’24US$7.45
US$13.61
+82.7%
28.0%US$19.00US$8.00US$10.1111
Jul ’24US$8.64
US$13.61
+57.5%
28.0%US$19.00US$8.00US$8.6111
Jun ’24US$8.49
US$13.61
+60.3%
28.0%US$19.00US$8.00US$8.4811
May ’24US$8.43
US$13.45
+59.6%
26.8%US$18.50US$8.00US$8.7611
Apr ’24US$9.04
US$13.45
+48.8%
26.8%US$18.50US$8.00US$9.8811
Mar ’24US$8.01
US$13.73
+71.4%
30.5%US$21.00US$8.00US$12.5111
Feb ’24US$9.27
US$13.45
+45.1%
32.6%US$21.00US$8.00US$10.9811
Jan ’24US$7.86
US$12.83
+63.3%
34.0%US$21.00US$8.00US$10.3912
Dec ’23US$7.73
US$12.31
+59.2%
39.1%US$21.00US$7.00US$9.1512
Nov ’23US$7.45
US$13.10
+75.8%
44.7%US$24.00US$7.00US$7.0212
Oct ’23US$6.15
US$20.98
+241.1%
52.7%US$45.00US$7.00US$6.3412

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies